home / stock / pbla / pbla news

PBLA News and Press, Panbela Therapeutics Inc Com From 07/19/23

Stock Information
Company Name: Panbela Therapeutics Inc Com
Stock Symbol: PBLA
Market: NASDAQ
Website: panbela.com
Menu
PBLA PBLA Quote PBLA Short PBLA News PBLA Articles PBLA Message Board
Get PBLA Alerts

News, Short Squeeze, Breakout and More Instantly...
PBLA - Panbela, 60 Degrees top healthcare gainers; Amarin, Aptevo among losers

2023-07-19 10:22:17 ET Gainers: Panbela Therapeutics ( PBLA ) +36% . 60 Degrees Pharmaceuticals ( SXTP ) +20% . CareMax ( CMAX ) +20% . Biodexa Pharmaceuticals ( BDRX ) +13% . bluebird bio ( BLUE ) +13% . Losers: Amar...
PBLA - Panbela Therapeutics skyrockets on $9.5M asset divesture

2023-07-19 10:03:43 ET Panbela Therapeutics ( NASDAQ: PBLA ) shares jumped nearly 40% in early trading on Wednesday after the company said it had divested certain assets in its eflornithine pediatric neuroblastoma program to US WorldMeds. Under the deal, Panbela w...

PBLA - Panbela Therapeutics to Receive a Total Up to $9.5 Million for Divestiture of Assets within Eflornithine (DFMO) Pediatric Neuroblastoma Program to US WorldMeds

MINNEAPOLIS and LOUISVILLE, Ky., July 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has divested certain assets in its eflornit...

PBLA - Panbela issued patent in Australia for a novel process to produce SPB-101

2023-07-17 08:55:08 ET Panbela Therapeutics ( NASDAQ: PBLA ) said Monday it received a patent in Australia for a novel process to produce SBP-101, its lead investigational product to treat pancreatic cancer tumors. The company was issued the Australian patent 201921...
PBLA - Panbela Announces Issuance of New Patent in Australia Patent is for Claims of a Novel Process for the Production of SBP-101

MINNEAPOLIS, July 17, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced an Issue Notification for the Australian paten...

PBLA - Panbela Announces Preliminary Safety Analysis for ASPIRE Trial

MMINNEAPOLIS, July 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announces that the independent Data Safety Monitoring Board (DSMB) of the Phas...

PBLA - InvestorNewsBreaks - Panbela Therapeutics Inc. (NASDAQ: PBLA) Closes on Public Offering Totaling About $8.5M

Panbela Therapeutics (NASDAQ: PBLA) , a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, has closed on its previously announced public offering. The offering consisted of 2,270,000 shares of its common stock or prefunded...
PBLA - Panbela Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis

MINNEAPOLIS, June 28, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the SWOG Cancer Research Network’s PACES S0820 Phase III t...

PBLA - Panbela Announces Poster Presentation at the Endocrine Society Meeting: Polyamine Inhibition and ?-Cell Preservation in Recent Onset Type 1 Diabetes

MINNEAPOLIS, June 26, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs announces a poster presentation highlighting the results for CPP...

PBLA - Panbela Announces Closing of Approximately $8.5 Million Public Offering

MINNEAPOLIS, June 21, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the closing of its previously announced public offering ...
Previous 10 Next 10